José Federico
Díaz González
Full Professor
Hospital General Universitario de Valencia
Valencia, EspañaPublications in collaboration with researchers from Hospital General Universitario de Valencia (16)
2024
-
Real-world persistence of initial targeted therapy strategy in monotherapy versus combination therapy in patients with chronic inflammatory arthritis
European Journal of Clinical Investigation, Vol. 54, Núm. 2
2023
-
Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study
RMD open, Vol. 9, Núm. 1
-
Long-term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis
Musculoskeletal Care, Vol. 21, Núm. 1, pp. 189-197
2022
-
Prevalence of symptomatic axial osteoarthritis phenotypes in Spain and associated socio-demographic, anthropometric, and lifestyle variables
Rheumatology International, Vol. 42, Núm. 6, pp. 1085-1096
2021
-
Comment on: Prevalence of systemic lupus erythematosus in Spain: higher than previously reported in other countries? Reply
Rheumatology (Oxford, England), Vol. 60, Núm. 3, pp. e120-e121
-
Factors associated with long-term retention of treatment with golimumab in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis: an analysis of the Spanish BIOBADASER registry
Clinical Rheumatology, Vol. 40, Núm. 10, pp. 3979-3988
2020
-
A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease
Scientific Reports, Vol. 10, Núm. 1
-
Fracture risk assessment in the general population in Spain by FRAX® algorithm. EPISER2016 study
Medicina Clinica, Vol. 154, Núm. 5, pp. 163-170
-
Prevalence of systemic lupus erythematosus in Spain: Higher than previously reported in other countries?
Rheumatology (United Kingdom), Vol. 59, Núm. 9, pp. 2556-2562
-
The prevalence of rheumatoid arthritis in Spain
Scientific Reports, Vol. 10, Núm. 1
2019
-
Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry
Rheumatology International, Vol. 39, Núm. 3, pp. 509-515
-
GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways
Nature Communications, Vol. 10, Núm. 1
-
Objectives and methodology of BIOBADASER phase III
Reumatologia Clinica, Vol. 15, Núm. 4, pp. 229-236
-
Prevalence of rheumatic diseases in adult population in Spain (EPISER 2016 study): Aims and methodology
Reumatologia Clinica, Vol. 15, Núm. 2, pp. 90-96
2018
-
Persistence and adverse events of biological treatment in adult patients with juvenile idiopathic arthritis: Results from BIOBADASER
Arthritis Research and Therapy, Vol. 20, Núm. 1